Advertisement

Topics

Tamoxifen Citrate in Patients With Breast Cancer

2014-08-27 03:19:51 | BioPortfolio

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer treatment.

PURPOSE: This phase III trial is studying blood samples to see how well a higher dose of tamoxifen citrate works in patients with breast cancer.

Description

OBJECTIVES:

Primary

- To determine how the increase of tamoxifen citrate dose influences the level of its major metabolites in the different genotype groups (poor-, intermediate-, and extensive-metabolizers) in patients with hormone-sensitive breast cancer.

Secondary

- To characterize the population pharmacokinetic profile of tamoxifen citrate and its metabolites, together with interpatient and intrapatient variability, and to quantify the influence of genetic and non-genetic factors on drug levels.

- To investigate the role of the other CYPs (specially CYP3A4, CYP2C19), conjugation enzymes, and drug transporters possibly involved in the metabolism of tamoxifen citrate, and assess the impact of their polymorphism on drug and metabolites levels.

- To confirm a relation between hot flashes and CYP2D6 genotypes and/or active metabolites levels, and to assess whether a systematic assessment of this clinical symptom could play a role in the monitoring of tamoxifen citrate treatment.

- To explore the correlation between genotypes/metabolites levels and clinical outcomes in terms of tumor relapse.

- To assess the feasibility, efficacy, and safety of concentration-guided adjustment of tamoxifen citrate dosage in CYP2D6 poor metabolizers to reach a predetermined range of endoxifen exposure.

- To conduct other exploratory analysis based on the eventual new data coming up in the future.

OUTLINE: Patients receive oral tamoxifen citrate (at a dose of 40 mg/day) daily for 4 months in the absence of disease progression or unacceptable toxicity.

Blood samples are collected for genotyping, phenotyping, and further analysis.

The results of the CYP2D6 genotyping may be communicated to the patients who are poor-metabolizers (if they choose to know the results), at the end of the 4 months.

Study Design

Masking: Open Label, Primary Purpose: Treatment

Conditions

Breast Cancer

Intervention

tamoxifen citrate, laboratory biomarker analysis, pharmacological study

Location

Centre Hospitalier Universitaire Vaudois
Lausanne
Switzerland
1011

Status

Recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:19:51-0400

Clinical Trials [4756 Associated Clinical Trials listed on BioPortfolio]

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb tri...

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer

This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating wom...

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see ...

Tamoxifen Citrate in Treating Premenopausal Women With Estrogen Receptor-Positive Breast Cancer

This randomized clinical trial studies tamoxifen citrate in treating premenopausal women with estrogen receptor (ER)-positive breast cancer. Estrogen can cause the growth of breast cancer ...

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood...

PubMed Articles [36270 Associated PubMed Articles listed on BioPortfolio]

Understanding tamoxifen adherence in women with breast cancer: A qualitative study.

Non-adherence to tamoxifen is common in breast cancer survivors and is associated with poor clinical outcomes. This study aimed to understand womens' experiences of taking tamoxifen and to identify fa...

Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.

Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated i...

Tamoxifen Prefabricated Beige Adipose Tissue Improves Fat Graft Survival in Mice.

Fat grafting has become an important tool for breast reconstruction in breast cancer patients. Tamoxifen is the hormone therapy agent most frequently used for breast cancer. Moreover, tamoxifen can af...

EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.

Enhancer of zeste homologue 2 (EZH2), a catalytic subunit of polycomb repressive complex 2, is overexpressed in a number of different tumors including breast cancer, and serves important roles in cell...

Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β-catenin signalling to restore tamoxifen sensitivity.

Tamoxifen is a first-line drug for hormone therapy (HT) in oestrogen receptor-positive breast cancer patients. However, 20% to 30% of those patients are resistant to tamoxifen treatment. Cancer stem c...

Medical and Biotech [MESH] Definitions

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Techniques which study entities using their topological, geometric, or geographic properties and include the dimension of time in the analysis.

A type of analysis in which subjects in a study group and a comparison group are made comparable with respect to extraneous factors by individually pairing study subjects with the comparison group subjects (e.g., age-matched controls).

A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.

An enzyme that, in the presence of ATP and COENZYME A, catalyzes the cleavage of citrate to yield acetyl CoA, oxaloacetate, ADP, and ORTHOPHOSPHATE. This reaction represents an important step in fatty acid biosynthesis. This enzyme was formerly listed as EC 4.1.3.8.

More From BioPortfolio on "Tamoxifen Citrate in Patients With Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Trial